The U.S. Food and Drug Administration has approved fingolimod capsules (Gilenya,™ Novartis International AG) for reducing the frequency of clinical relapses and delaying the accumulation of physical disability in relapsing forms of MS, making it the first oral disease-modifying therapy for the treatment of multiple sclerosis. According to Novartis, the drug will be available for prescription in coming weeks.
If you would like to read the entire article go here.
Maybe someday soon Avonex shots will be a distant memory for me!!!